Clinical Trial Update: Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating deferasirox for treating transfusional iron overload in patients with myelodysplastic syndrome has completed with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iron Overload
• Myelodysplastic Syndrome

Drugs mentioned

• Deferasirox (Deferasirox)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Myelodysplastic Syndrome, Iron Overload | Phase 2 | Status: COMPLETED | Results posted: 2021-08-16